Phathom Pharmaceuticals Inc’s Market Journey: Closing Weak at 10.24, Down -5.54

Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.

The closing price of Phathom Pharmaceuticals Inc (NASDAQ: PHAT) was $10.24 for the day, down -5.54% from the previous closing price of $10.84. In other words, the price has decreased by -$5.54 from its previous closing price. On the day, 0.53 million shares were traded. PHAT stock price reached its highest trading level at $11.0213 during the session, while it also had its lowest trading level at $10.155.

Ratios:

Our analysis of PHAT’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 10.22 and its Current Ratio is at 10.25.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Stifel on May 03, 2024, initiated with a Buy rating and assigned the stock a target price of $24.

On January 05, 2024, Needham reiterated its Buy rating and also lowered its target price recommendation from $23 to $26.

On August 09, 2023, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $28.H.C. Wainwright initiated its Buy rating on August 09, 2023, with a $28 target price.

Insider Transactions:

Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Apr 08 ’24 when Henderson Molly sold 3,435 shares for $11.10 per share. The transaction valued at 38,128 led to the insider holds 95,263 shares of the business.

Curran Terrie sold 16,851 shares of PHAT for $153,513 on Mar 22 ’24. The President and Chief Executive now owns 410,784 shares after completing the transaction at $9.11 per share. On Jan 24 ’24, another insider, TAKEDA PHARMACEUTICAL CO LTD, who serves as the 10% Owner of the company, sold 3,703,703 shares for $8.10 each. As a result, the insider received 29,999,994 and left with 3,755,583 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PHAT now has a Market Capitalization of 599286784 and an Enterprise Value of 663371904. For the stock, the TTM Price-to-Sale (P/S) ratio is 880.64. Its current Enterprise Value per Revenue stands at 972.686 whereas that against EBITDA is -3.979.

Stock Price History:

Over the past 52 weeks, PHAT has reached a high of $17.02, while it has fallen to a 52-week low of $6.07. The 50-Day Moving Average of the stock is 4.62%, while the 200-Day Moving Average is calculated to be 2.32%.

Shares Statistics:

PHAT traded an average of 897.09K shares per day over the past three months and 572350 shares per day over the past ten days. A total of 57.97M shares are outstanding, with a floating share count of 28.13M. Insiders hold about 51.90% of the company’s shares, while institutions hold 47.44% stake in the company. Shares short for PHAT as of 1713139200 were 12032035 with a Short Ratio of 13.41, compared to 1710460800 on 10444308. Therefore, it implies a Short% of Shares Outstanding of 12032035 and a Short% of Float of 42.240003.

Most Popular

[the_ad id="945"]